News
06-05-2011, 10:27 PM
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
More... (http://www.news-medical.net/news/20110606/Alnylams-ALN-VSP-Phase-I-trial-data-on-liver-cancer-presented-at-ASCO-2011.aspx)
More... (http://www.news-medical.net/news/20110606/Alnylams-ALN-VSP-Phase-I-trial-data-on-liver-cancer-presented-at-ASCO-2011.aspx)